HLA-A2 tumor associated antigen peptides and compositions
A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
1. A composition, comprising LLTFWNPPV (SEQ ID NO:4), KVFGSLAFV (SEQ ID NO:7), KLBPVQLWV (SEQ ID NO:6), SMPPPGTRV (SEQ ID NO:5), YLSGADLNL (SEQ ID NO: 8), IMIGHLVGV (SEQ ID NO:9), KVAEIVHFL (SEQ ID NO:10), RLLQETELV (SEQ ID NO:2), YLQLVFGIEV (SEQ ID NO:3), and aKXVAAWTLKAAa (SEQ ID NO:1), wherein a in SEQ ID NO:1 is any of D-alanine or L-alanine and wherein X in SEQ ID NO:1 is any of cyclohexylalanine, phenylalanine or tyrosine and wherein B in SEQ ID NO:6 is any of α-amino butyric acid or cysteine.
2. The composition of claim 1 , which further comprises an adjuvant.
3. The composition of claim 2 , wherein said adjuvant is a mineral oil adjuvant.
4. The composition of claim 1 , wherein the first a in SEQ ID NO:1 is L-alanine and the last a in SEQ ID NO:1 is D-alanine.
5. The composition of claim 1 , wherein a in SEQ ID NO:1 is D-alanine.
6. The composition of claim 1 , wherein X in SEQ ID NO:1 is cyclohexylalanine.
7. The composition of claim 1 , wherein the first a in SEQ ID NO:1 is L-alanine and the last a in SEQ ID NO:1 is D-alanine and wherein X in SEQ ID NO:1 is cyclohexylalanine.
8. The composition of claim 1 , wherein a in SEQ ID NO:1 is D-alanine and wherein X in SEQ ID NO:1 is cyclohexylalanine.
9. The composition of claim 1 , wherein B in SEQ ID NO:6 is α-amino butyric acid.
10. A method of delaying the recurrence of cancer following surgery, chemotherapy or radiation comprising administering the composition of claim 1 to a patient.
11. The method of claim 10 , wherein said cancer is selected from the group consisting of:
a. colon cancer;
b. non-small cell lung cancer (NSCLC);
c. breast cancer;
d. ovarian cancer; and
e. a cancer of the head and/or neck.